Myriad Genetics (MYGN) Announces EndoPredict Shown in Second Study to be More Effective than Oncotype DX in Women with Intermediate Risk of Breast Cancer Recurrence
Tweet Send to a Friend
Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, today announced new positive results for EndoPredict® ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
